Cargando…

Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype?

Detalles Bibliográficos
Autores principales:	Kow, C.S., Hasan, S.S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577654/ https://www.ncbi.nlm.nih.gov/pubmed/33158786 http://dx.doi.org/10.1016/j.pulmoe.2020.10.004

Ejemplares similares

Colchicine for COVID-19: Hype or hope?
por: Kow, Chia Siang, et al.
Publicado: (2022)

Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19
por: Gade, Akhil R., et al.
Publicado: (2020)

Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’
por: Kow, Chia Siang, et al.
Publicado: (2023)

Internet addiction disorder: Hype, a myth
por: Bipeta, Rajshekhar
Publicado: (2016)

Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19
por: Di Nisio, Marcello, et al.
Publicado: (2021)

Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series
por: Yang, Stephen Su, et al.
Publicado: (2021)

Extracorporeal Membrane Oxygenation in COVID-19 Patients: More Hype than Substance?
por: Trikha, Anjan, et al.
Publicado: (2021)

Thulium fiber laser lithotripsy: Is it living up to the hype?
por: Denstedt, John, et al.
Publicado: (2023)

Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells
por: Lokau, Juliane, et al.
Publicado: (2020)

Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES)
por: Stredny, Coral M., et al.
Publicado: (2020)

Response to “Letter To Editor: Internet addiction disorder: Hype, a myth”
por: Dalal, P. K., et al.
Publicado: (2016)

Artificial intelligence in ophthalmology: Is it just hype with no substance or the real McCoy
por: Patil, Santosh V
Publicado: (2019)

Radial Artery Cannulation at the Anatomical Snuffbox: Hype or Hope in Interventional Cardiology?
por: Taylan, Gökay, et al.
Publicado: (2021)

Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series
por: Nakamura, Hideta, et al.
Publicado: (2020)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

In response to: “Radial Artery Cannulation at the Anatomical Snuffbox: Hype or Hope in Interventional Cardiology?”
por: Soydan, Elton, et al.
Publicado: (2021)

Metformin in COVID-19: clinical trials are needed to prove its benefits
por: Kow, Chia Siang, et al.
Publicado: (2022)

Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia
por: Fomina, Daria S., et al.
Publicado: (2020)

Impact of Interleukin-6 Receptor Blockade With Tocilizumab on Cardiac Injury in Patients With COVID-19: A Retrospective Cohort Study
por: Weber, Brittany N, et al.
Publicado: (2021)

Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis – Author’s reply
por: Kashour, Tarek, et al.
Publicado: (2021)

Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Fioravanti, Antonella, et al.
Publicado: (2020)

Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure()
por: Kow, C.S., et al.
Publicado: (2022)

Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020)

Tratamiento con glucocorticoides en pacientes con COVID-19 e insuficiencia cardíaca concurrente
por: Kow, C.S., et al.
Publicado: (2022)

Tocilizumab administration in a refractory case of COVID-19
por: Dastan, Farzaneh, et al.
Publicado: (2020)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
por: Gupta, Rahul
Publicado: (2022)

Prevalence of Frailty in Patients with COVID-19: A Meta-Analysis
por: Kow, Chia Siang, et al.
Publicado: (2020)

Re: ‘Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis’ by Tleyjeh et al.
por: Koeckerling, David, et al.
Publicado: (2021)

Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade
por: Carvajal Alegria, Guillermo, et al.
Publicado: (2021)

Cytomegalovirus Viremia, Pneumonitis, and Tocilizumab Therapy
por: van Duin, David, et al.
Publicado: (2011)

Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?
por: Mantero, Vittorio, et al.
Publicado: (2020)

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
por: Michot, J.-M., et al.
Publicado: (2020)

Authors’ Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Liu, Bin, et al.
Publicado: (2020)

Azithromycin in patients with COVID-19: Friend or foe?
por: Kow, Chia Siang, et al.
Publicado: (2021)

Pharmacologic therapeutic options for thromboprophylaxis in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Revascularization in COVID-19 patients with renal infarction
por: Kow, Chia Siang, et al.
Publicado: (2021)

Macrolides for patients with COVID-19 and concurrent pertussis infection
por: Kow, Chia Siang, et al.
Publicado: (2021)

Use of Azithromycin in COVID-19: A Cautionary Tale
por: Kow, Chia Siang, et al.
Publicado: (2020)

The use of antimotility drugs in COVID-19 associated diarrhea
por: Kow, Chia Siang, et al.
Publicado: (2021)

The use of antiplatelet agents for arterial thromboprophylaxis in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_md3g7nhtpbo7flb2fg3700nphr